AKT1 and prostate carcinoma: In prostate cancer cells, the relative activity of AKT/mTOR and MNK/eIF4E pathways are under a controlled balance; mTOR and MNK concomitant inhibition had higher suppression of prostate cancer cell cycle progression and cell proliferation than inhibition of only one of them via phosphorylated eIF4E9.